All In MedTech

Device Trial Radar · NCT00269230

Attain StarFix™ Model 4195 Left Ventricular Lead

Last checked: Nov 20, 2026Latest source record: Nov 20, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

441

Actual

Start

Jul 2004

Primary completion

Jul 2005

Study completion Jul 2005

Sponsor

Sponsor type
Industry
First posted
Dec 23, 2005

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

People who have abnormal heart beats, or whose heart does not beat on its own, may need an electronic device called a pacemaker or a defibrillator. Furthermore, people whose hearts have a reduced pumping ability may need a device are called cardiac resynchronization therapy (CRT) device. A CRT device is implanted surgically just under the skin in the upper chest area. This device then helps the heart beat at a regular rhythm by sending electrical signals (pacing) directly to the heart tissue through flexible wires called leads. The device may also be able to stop the heart from beating too fast. Three leads are implanted into the chambers of your heart. Two of the leads will be placed on the right side of your heart. The third lead is placed on the left side of your heart and is the lead being studied. The purpose of this study is to evaluate the safety and efficacy of the Attain StarFixTM Model 4195 Left Ventricular (LV) Lead. This particular model lead has special characteristics that may help to better keep it in position once it is implanted into the left ventricle. It is also "steroid-eluting" which means that over time it slowly releases a small amount of medication into the heart tissue to help prevent too much swelling around the area it is implanted.

Conditions

  • Heart Failure

Interventions

  • Pacing LeadDevice

    Left ventricular pacing lead

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Efficacy at 3 monthsTime frame: 3 Months

Locations

25 sites in 3 countries. Site status is shown where the registry gives one.

  • Site not named

    Long Beach, California

24 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.